Identifying and explaining the variability in development and implementation costs of disease management programs in the Netherlands

Table 1 Descriptive statistics

	Mean	SD	Median	Min	Max	IQR
Development duration (months)	12	6	12	3	25	6
Patients participating in DMP^#	801	986	300	75	3,400	957
Organization FTEs^#	433	841	33	1	2,850	256
DMP FTEs	0.76	0.58	0.60	0.10	2.50	0.63
Development costs^#	75,832	72,727	49,972	5,891	274,783	85,917
Annualized development costs	69,749	47,807	48,141	7,855	198,188	66,704
Implementation costs	100,827	86,776	74,836	7,278	387,879	117,079
PACIC at baseline^# (1-5 best)	2.88	0.29	2.81	2.25	3.60	0.35
PACIC at year 1^# (1-5 best)	2.95	0.28	2.99	2.44	3.62	0.40

^#The Kolmogorov-Smirnoff test rejected the assumption of normally distributed data; SD: standard deviation; min: minimum; max: maximum; IQR: interquartile range (Quartile 3-Quartile 1); FTE: full-time equivalent; implementation costs accrued within the first calendar year of DMP implementation.

ISSN: 1472-6963